Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report - Top-Institutions - MDSpire

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

By
Carlen A. Yuen
Mahbod Jafarvand
David O. Kamson
Eleanor Chu
Jennifer E. Soun
William H. Yong
Frank P. Hsu
Hansen Bow
Michelle Zheng
Shyam M. Srinivas
June 11, 2026
0 min

Frontiers In Oncology

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

National Cancer Institute

Bethesda, Maryland
Key Differentiators
- Oncology
#2

National Institutes of Health

Bethesda, Maryland
Key Differentiators
- Oncology
#3

Center for Cancer Research

Bethesda, Maryland
Key Differentiators
- Oncology
#4

University of California, Los Angeles

Los Angeles, California
Key Differentiators
- Oncology
#5

The University of Texas MD Anderson Cancer Center

Houston, Texas
Key Differentiators
- Oncology

Original Source(s)

Frontiers In Oncology

Combined SSTR2-targeted Analogue with 177Lu-DOTATATE radionuclide and octreotide therapy for refractory meningioma: a case report

by Carlen A. Yuen, Mahbod Jafarvand, David O. Kamson, Eleanor Chu, Jennifer E. Soun, William H. Yong, Frank P. Hsu, Hansen Bow, Michelle Zheng, Shyam M. Srinivas
June 11, 2026

Related Content

Frontiers In Immunology

Correction: Converting an immunologically “cold” tumor: Exceptional response to cadonilimab plus chemotherapy in microsatellite-stable pancreatic cystadenocarcinoma

by Chunxiao Ni, Jiaju Xu, Yu Pang
June 10, 2026

Frontiers In Immunology

Spatial immune archetypes in gastric and colorectal cancer: a proposed conceptual framework for immunotherapy resistance and therapeutic remodeling

by Songlin Sun, Yicong Zeng, Jiahan Chen, Yang Zhong, Tong Zhou
June 11, 2026

Frontiers In Immunology

Why CAR T cell therapy fails in renal cell carcinoma

by Hua-jun Zhang, Lv-zhou Han, Xiang Zhang, Yang-lu Ge
June 11, 2026